BPA for IV Fluids on an "As Needed Basis"
Indian Health Service · Crownpoint, NM
Why this score
Typical award ~$1.5M, new this week; but only 3 days left.
Solicitation # S-195396Updated Jun 4, 2026Scored Nov 20, 2026
Dec 3
Dec 3, 2026, 5:00 PM MST
Summary by RFP Detector
Department of Energy (Triad - DOE Contractor) posted a special notice titled “TECHNOLOGY LICENSING OPPORTUNITY: Clathrate Therapeutics Platform” under solicitation number S-195396. It was posted on Jun 4, 2026. Responses are due Dec 3, 2026, 5:00 PM MST. It is classified under NAICS 325412 (Pharmaceutical Preparation Manufacturing) and product/service code 6505. No set-aside is listed. The place of performance is Los Alamos, New Mexico. The listed point of contact is Caleb Ledgerwood.
RFP Detector Score
Every RFP starts at 50. Each factor adds or subtracts points compared with a typical RFP; unknown data counts as neutral.
Starts at 50
No value published. Typical award is about $136K: the median of 5,331 federal contracts over $25K awarded in NAICS 325412, FY24–FY26.
Full and open competition. The largest recipient took 91% of these dollars in FY24–FY26, so expect a strong incumbent.
Across all agencies, NAICS 325412 saw 59,093 contracts worth $39.2B in FY24–FY26. No agency-specific history found. 83 other notices from this office in the past 12 months.
Special notice: 14 days to respond (due Dec 3, 2026, 5:00 PM MST).
Documents not listed, 2 named contacts with email, 538-word description.
Posted 169 days ago.
50 + contributions = 45 (D, Limited)
Informational, not advice to bid or not bid. Score version 1.0.0, evaluated Nov 20, 2026.
Eligibility · Full and open competition
Full and open competition means the notice states no set-aside: any responsible business can respond, subject to the requirements in the notice.
Not stated in a form we could extract. See the official solicitation for requirements, evaluation criteria and submission steps.
From the official notice
This technology from scientists at Los Alamos National Laboratory represents a novel platform for improving the safety and effectiveness of therapeutic gas-based treatments by enabling controlled, localized delivery at the site of disease. By addressing longstanding challenges associated with systemic exposure and dosing precision, the platform enhances the clinical viability of gas therapies across high-value markets such as oncology, cardiovascular care, and regenerative medicine. In addition, the inclusion of a complementary predictive modeling capability supports treatment optimization and development efficiency, reducing technical risk and accelerating translation. Together, these capabilities position the technology as a differentiated and scalable solution that can unlock new commercial opportunities in areas where gas-based therapeutics have shown promise but faced delivery limitations. The Opportunity: Therapeutic gases have demonstrated meaningful biological effects across oncology, cardiovascular disease, neuroprotection and regenerative medicine, yet their clinical adoption has been limited by a fundamental challenge: safe, controlled and localized delivery. Existing approaches often result in rapid release, systemic exposure or narrow therapeutic windows, creating safety, regulatory and development barriers. The Clathrate Therapeutics Platform addresses this unmet need by positioning gas-based therapies as programmable, targetable and commercially viable treatment modalities. By enabling more precise control over where and how therapeutic gases are delivered, the platform has the potential to unlock new product categories, enhance combination treatment strategies and accelerate translation of gas-based therapeutics into high-value clinical markets. How it Works: The Clathrate Therapeutics Platform uses a proprietary, controlled-release system designed to localize therapeutic gases at the intended treatment site rather than allowing them to disperse systemically. This technology temporarily stabilizes the gas within a biocompatible structure that gradually releases it under physiological conditions, enabling sustained and targeted exposure. This controlled release approach is designed to support therapeutic concentrations where needed while limiting circulating levels elsewhere in the body. An integrated computational modeling capability further supports optimization of dosing profiles and treatment parameters, helping guide development decisions prior to in vivo studies. Key Advantages: Localized delivery: Targets therapeutic gases to the intended site while minimizing systemic exposure. Controlled release: Designed for sustained, tunable dosing under physiological conditions. Improved safety margin: Aims to separate therapeutic effect from toxicity risk. Platform versatility: Applicable across oncology, cardiovascular, neurological and regenerative indications. Development optimization: Supported by predictive modeling to guide dose and design decisions. Partnership-ready architecture: Suitable for integration with drug-device combinations and existing treatment modalities. Market Applications: Oncology Therapeutics Industry Cardiovascular and Vascular Medicine Industry Neurology and Neurodegenerative Disease Sector Regenerative Medicine and Tissue Engineering Industry Medical Device and Drug-Device Combination Companies Biotechnology and Specialty Pharma Companies Computational Drug Development and Modeling Firms Development Status: TRL 2 US patent pending LA-UR-26-22810 LANL Tech Partnerships: Unlock the Innovative Potential Los Alamos National Laboratory offers a wide range of cutting-edge technologies and capabilities that may provide your company with a competitive edge in the market and unlock the innovative potential that can enhance, refine, and revolutionize your products. LANL’s licensing program focuses on moving inventions developed by our researchers to commercial innovations. Patented and patent pending inventions and copyrighted software are available to existing and start-up companies through exclusive and non-exclusive licensing agreements. For specific discussions, please contact licensing@lanl.gov. Note: This is not a call for external services for the development of this technology. https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology m.lanl.gov/tech-search
No documents are listed for this notice.
Caleb Ledgerwood
PrimaryLindsay Augustyn
Points of contact as published on the notice.
Special Notice posted
Responses dueNext · in 14 days
Archive date on the official notice
Federal award history
All agencies · NAICS 325412 · FY24–FY26
Recipients of past awards in this market, not the incumbent of this RFP.
| Fiscal year | Obligated ($) |
|---|---|
| FY2022 | 34,447,590,288.98 |
| FY2023 | 12,775,984,028.51 |
| FY2024 | 10,077,505,585.41 |
| FY2025 | 13,091,276,241.59 |
| FY2026 | 15,989,424,529.87 |
Federal contract award records, award types A–D, FY24–FY26. Updated Nov 15, 2026.
Same NAICS group or Healthcare & Medical, nearby first, ranked by score.
Indian Health Service · Crownpoint, NM
Why this score
Typical award ~$1.5M, new this week; but only 3 days left.
Indian Health Service · Santa Fe, NM
Why this score
New this week, clear, complete notice; but small typical award (~$120K).
Indian Health Service · Zuni, NM
Why this score
ISBEE set-aside, new this week; but small typical award (~$88K).
Indian Health Service · New Mexico
Why this score
75 days to respond, restricted competition; but posted 287 days ago.
Department of Veterans Affairs · Albuquerque, NM
Why this score
SDVOSB set-aside, active buyer ($4B FY24–FY26); but only less than a day left.
City of Albuquerque Department of Health, Housing & Homelessness · Albuquerque, NM
Why this score
15 days to respond, recently updated; but few similar RFPs.
RFP Detector Scores are informational.How we score →
124 open RFPs from this issuer and its offices.
Department of Energy
Why this score
8(a) set-aside (strong incumbent); but only less than a day left.
Department of Energy
Why this score
Posted 10 days ago; but only less than a day left.
Department of Energy · Oak Ridge, TN
Why this score
Full and open, new this week; but only less than a day left.
Department of Energy · Upton, NY
Why this score
New this week, active market ($875M FY24–FY26); but only less than a day left.
Department of Energy · Oak Ridge, TN
Why this score
New this week, active market ($760M FY24–FY26); but only less than a day left.
Department of Energy · Upton, NY
Why this score
Active market ($1.1B FY24–FY26), new this week; but only less than a day left.
RFP Detector Scores are informational.How we score →
Official federal notice. Updated Jun 4, 2026.
Official solicitation:Sign in free to open the official solicitation
RFP Detector is an independent service and is not affiliated with any government agency. Scores are informational.
RFP Detector is not affiliated with the organization that issued this RFP. Always rely on the official notice and confirm every date and requirement with the issuer.